Articles tagged with Cancer Treatments
A new study from Aarhus University reveals the thymus, a small organ previously believed to cease functioning early in adult life, plays a lifelong role in the risk of cancer and cardiovascular disease. The healthier the thymus, patients respond better to immunotherapy treatment.
A new clinical trial will investigate whether adding the oral medication vorasidenib to standard chemotherapy improves progression-free survival for people with newly-diagnosed, grade 3 IDH-mutant astrocytoma. The study aims to recruit 400 individuals with this type of brain cancer and evaluate the safety and side-effect profile of the...
A recent study found that women have a 21% lower risk of death compared to men, but a 12% higher risk of severe side effects from cancer treatment. The research, conducted in partnership with international collaborators, analyzed data from over 20,000 cancer patients and identified sex-based differences in survival and treatment toxicity.
Researchers have identified and resolved molecular bottlenecks to produce doxorubicin, a vital chemotherapy agent, resulting in a 180% increase in production. This breakthrough enables cost-effective manufacturing of essential antibiotics and anti-cancer agents, promising a cleaner and more reliable supply of life-saving medicines.
Researchers explored using CDK4/6 inhibitors to treat PDAC by targeting RB1, which is often inactivated by oncogenic KRAS. This approach showed promise in inducing cellular senescence, but further combination therapy is needed for therapeutic benefit.
The NRG-LU005 trial found that immunotherapy atezolizumab did not improve survival for patients with limited-stage small cell lung cancer when added to chemoradiation. Twice-daily radiation therapy, however, was associated with improved survival in this population.
Recent advances in photonic nanomaterials and healthcare devices have led to the development of wearable and implantable medical devices. These devices utilize light for precise manipulation of cells and tissues, offering new possibilities for early disease detection, light-based therapies, and personalized precision medicine.
A phase 3 clinical trial by Mass General Brigham reveals romiplostim's ability to prevent chemotherapy-induced thrombocytopenia, allowing full-dose chemotherapy delivery. The medication boosts bone marrow's resistance to chemotherapy, reducing the risk of life-threatening bleeding and improving cancer treatment outcomes.
The Sylvester Cancer Tip Sheet for March 2026 highlights the importance of genetic testing for cancer risk assessment. Researchers have made significant progress in developing new treatments, including mRNA-based immunotherapy for colorectal and pancreatic cancers. Additionally, the Dolphins Cancer Challenge has surpassed $100 million ...
Researchers discovered yaku'amide B induces CD9 degradation, a cancer stem cell-related protein, in addition to inhibiting ATP synthase, leading to cellular energy depletion and cancer cell suppression. This natural compound has potential as a new therapeutic approach for cancer treatment.
The Alliance trial explores the combination of zanubrutinib and sonrotoclax for CLL treatment, aiming to send cancer into remission and allow patients to stop treatment earlier. The study has the potential to be life-changing for patients and their families, reducing the burden of ongoing therapy and improving quality of life.
Researchers discover a potential chemotherapy agent that causes cancer cells to release signals similar to those released by infected cells, triggering an immune response. This finding could lead to a new approach in cancer treatment, using lower doses of chemotherapy drugs to recruit the immune system as an ally.
Blocking two key 'don't eat me signals' in cancer cells heightens the immune response and sensitizes tumors to immunotherapy in glioblastoma models. Researchers found that simultaneously blocking CD47 and CD24 improved immunotherapy response, allowing macrophages to better recognize and attack cancer cells.
Researchers at Weill Cornell Medicine have identified the FOXJ1 gene as a key player in chemotherapy resistance in prostate cancer. The study found that increased FOXJ1 levels in tumors can make cancer cells less responsive to taxane chemotherapy, leading to poorer outcomes for patients.
Ochsner MD Anderson Cancer Center will be the first in the southern US to offer biology-guided radiotherapy (BgRT), a breakthrough treatment that uses cancer biology to guide radiotherapy delivery. This new therapy aims to provide more focused and accurate treatment with fewer side effects for patients.
The Alliance for Clinical Trials in Oncology is spotlighting new trials for colorectal cancer in March, focusing on early detection methods and treatments for treatment delays and loss of appetite. The trials aim to improve patient outcomes, with several enrolling patients with newly diagnosed colon or rectal cancer.
Singapore's breast cancer incidence is rising, but mortality rates are falling, mirroring global trends. The country's strong healthcare system and high-screening participation have contributed to improved survival rates.
A new study demonstrates that blocking a signaling protein called FAK helps mobilize an anti-tumor immune response, allowing tumor-fighting cells to approach tumors and shift the behavior of other immune cells to work against them. This approach achieved the best effects on immune cell recruitment, tumor size reduction, and survival ti...
A new study from Memorial Sloan Kettering Cancer Center reveals that analyzing a patient's genomic profile can predict breast cancer resistance to CDK4/6 inhibitors. The researchers found that inheriting a BRCA2 mutation and other genetic alterations increase the likelihood of resistance. This discovery provides a new strategy for pred...
The study discovered that restoring cellular vibration decreases cancer growth and severity in laryngeal cancer. Researchers exposed cancer cells to sound-wave vibration, leading to a decrease in a protein promoting cancer growth.
A study published in Science Advances reveals a mechanism to bind to intrinsically disordered proteins, providing a new approach for therapeutic design. The research, led by Dr. Xavier Salvatella, shows that these proteins adopt more organized conformations when clustering, allowing for selective binding by a drug.
Researchers developed a light-responsive nanoassembly that enables precise and controllable drug delivery inside tumor cells. The strategy achieves strong tumor suppression while effectively inhibiting tumor spread, without causing noticeable systemic toxicity.
The article summarizes updated recommendations on fertility preservation in people with cancer, considering potential health risks to offspring and treatment side effects. Clinicians should inform patients about available options before treatment initiation.
A new UCLA study suggests that adding hormone therapy to post-operative radiotherapy may provide little survival benefit for most men with prostate cancer, especially those with low PSA levels. However, men with higher PSA levels before radiation may see modest improvements in survival and metastasis-free survival.
Researchers have developed a new type of cell therapy called HIT cells that can detect and eliminate cancer cells in mice with pancreatic, kidney and ovarian cancers. The treatment shows promise for nearly 20 other types of cancers, including glioblastoma and pancreaticadenocarcinoma.
Daily aspirin use offers no quick or reliable way to prevent bowel cancer in the general population, increasing risk of serious bleeding. However, it may have potential long-term benefits for people at high genetic risk of colorectal cancer.
A research team has engineered bacteria capable of consuming tumours from the inside out, using a novel tool for cancer treatment. The bacteria, Clostridium sporogenes, are designed to multiply in oxygen-free environments found in solid tumours, where they can effectively target and destroy cancerous cells.
Scientists developed a new platform using protein-like polymers to target and degrade cancer-driving proteins like MYC and KRAS. The approach triggers cancer cell death, offering hope for treating aggressive and drug-resistant cancers.
The foundation awarded $400,000 over two years to five early-career researchers and continuation support to three current Innovators with significant progress on their proposed research. The recipients focus on developing targeted therapeutics, decoding dendritic cell function, defining NKT cell interactions with tumors, engineering T ...
A Singapore study reveals that a specific gene called SERPINE1 drives resistance to chemotherapy and cancer spread in colorectal cancer patients. The findings also identify a molecular signature called RESIST-M, which can predict poorer survival and higher relapse risk, supporting earlier intervention and more targeted follow-up care.
Researchers found that radiation-resistant cancer cells are vulnerable to NK cell-mediated killing due to increased expression of specific cellular membrane proteins, creating an 'evolutionary double-bind'. The combination of radiation therapy and NK cell-based immunotherapy was more effective in suppressing both sensitive and resistan...
A new study examines the mechanisms, clinicopathological features, and management strategies of GI toxicity induced by targeted cancer therapies. The authors highlight the importance of close collaboration between oncologists, gastroenterologists, and pathologists to ensure accurate diagnosis.
Researchers at the Center for Cell-Based Therapy developed a new approach to enhance CAR-NK cell cytotoxicity, combining optimized co-stimulation with reversible pharmacological control. The study showed increased tumor control in animal models, paving the way for improved cancer treatment.
Xiwen Gong and Zhen Xu, both from the University of Michigan Engineering, received the award for developing optoelectronics and histotripsy, a cancer treatment using sound waves. The new treatment can spare patients from chemotherapy and radiation therapy.
Researchers have identified specific changes in genetic material that can predict the effectiveness of chemotherapy in young adults with germ cell tumors. A blood test based on these changes could help doctors make personalized decisions about treatment.
Studies presented at the inaugural Multidisciplinary Radiopharmaceutical Therapy Symposium highlight the growing potential of RPTs to improve cancer outcomes. A meta-analysis shows Lu-177 PSMA-617 consistently prolongs progression-free survival without adding severe side effects for patients with advanced prostate cancer.
The Mayo Clinic has installed the first magnetic nanoparticle-mediated hyperthermia machine for cancer research in the US. This innovative technology uses heat to damage and kill cancer cells, offering a new angle in cancer treatment and potentially improving outcomes for patients with resistant tumors.
The conference aims to improve genetic studies, clinical best practices and community interventions to combat the increasing cancer incidence rates. It will bring together top cancer-focused minds to promote precision medicine and stimulate multidisciplinary collaborations for cancer solutions.
Researchers developed a new computational approach to predict chemotherapy response in triple-negative breast cancer, outperforming current methods. The TmS biomarker accurately sorts patients into those with favorable or poor prognosis, highlighting its potential as an effective starting point for patient stratification.
Research at University of Seville and CABIMER reveals circadian protein Cryptochrome1 regulates DNA repair in response to time of day. Effective radiotherapy timing found to improve sensitivity of breast and prostate cancers, but not lung or glioma cancers.
Researchers have engineered Listeria bacteria to stimulate the body's innate immune system and eliminate cancer cells. The therapy, which boosts gamma delta T cells, shows promise in treating children with leukemia and preventing graft-versus-host disease.
Researchers used Caenorhabditis elegans to model chemotherapy-induced neurological dysfunction and tested two compounds for improved recovery. Both sildenafil citrate and Resveramorph-3 significantly reduced seizure-like behaviors and duration, suggesting their potential as therapeutic candidates.
Researchers have discovered a new mechanism by which an existing cancer drug can block the loss of BCMA molecules on cancer cells, allowing CAR T cell therapy to become effective again in some patients. The study shows that carfilzomib can prevent the degradation of BCMA and restore its presence on the surface of malignant plasma cells.
Researchers identified blood-based biomarkers that can help distinguish patients with glioblastoma who are most likely to live longer from novel treatment with an engineered oncolytic virus. The study found that adding an immune booster increased survival times and improved immunological fitness.
Researchers found that PSMA PET/CT scans can help guide treatment planning and improve long-term outcomes for patients with recurring prostate cancer. The study suggests that incorporating these scans into routine care may lead to better results and reduced side effects.
A new study suggests blocking key protein p300 can create novel form of cellular stress in cancer cells, re-sensitizing chemo-resistant tumors. Cells produce proteins even with damaged DNA, leading to toxic buildup and stress inside the cell's internal quality-control system.
The National Comprehensive Cancer Network (NCCN) has committed to updating its robust information resources for cancer patients and caregivers annually, available in both English and Spanish. The updated resources will provide factual, trustworthy information to guide patients and caregivers towards their best possible outcome.
Researchers at the University of Virginia Health System have identified a molecule that blocks the gene responsible for glioblastoma, a fast-growing and deadly brain cancer. The compound shows promise in preventing the invasive cancer from spreading through the brain without causing harm to healthy tissue.
Engineered yeast cells can mimic real cancer cells and be used to test new cancer immunotherapies much faster and cheaper than before. This new technology enables researchers to assess which CAR T variants are most promising much more quickly, leading to safer and more targeted cancer treatments.
A team of researchers at VCU Massey Comprehensive Cancer Center has discovered an innovative way to use a drug already approved in treating irregular heartbeat to selectively target specific functions of enzymes in lymphoma, effectively killing cancer cells and reducing tumor growth with little to no toxicity. The study found that RBF4...
A national clinical trial found that oxybutynin significantly reduced hot flash frequency and quality of life for men undergoing hormone therapy for prostate cancer. The study showed substantial improvements in hot flash symptoms, often within the first week of treatment.
Researchers developed an AI tool called ONCO-ACS to predict the risk of secondary heart attacks in cancer patients after a heart attack. The tool combines cancer-related factors with standard clinical data to provide reliable information for doctors to balance treatment benefits and harms.
The PATINA trial demonstrates a significant progression-free survival benefit with palbociclib in patients with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-positive (HER2+) metastatic breast cancer. The study showed a median progression-free survival of 44.3 months, compared to 29.1 months in the control arm.
A new AI tool has been developed to predict the chances of death, major bleeding, or another cardiac event in cancer patients who have had a heart attack. The ONCO-ACS score combines cancer-related factors with standard clinical data to provide individualized treatment recommendations.
Researchers developed a new framework called SOLVE to overcome data challenges in precision cancer treatment. By jointly modeling known and unknown factors, SOLVE provides a robust tool for biomarker discovery and investigating tumor responses.
A clinical trial has shown that a novel cooled laser focal therapy device can effectively treat prostate cancer with minimal side effects. The treatment provided similar cancer-related outcomes to traditional methods but with an improved safety profile and low rates of incontinence.
Researchers identified statins as a potential booster for cancer immunotherapy by preventing the release of PD-L1-containing sEVs. Statin treatment suppressed UBL3 modification, reduced PD-L1 sorting into sEVs, and improved survival outcomes in lung cancer patients.
A large multinational clinical trial found that giving healthcare providers access to patient-reported outcome (PRO) data significantly improves the consistency of how treatment-related side effects are assessed in patients with cancer. This study highlights the importance of integrating the patient's voice into routine clinical evalua...
Research suggests that blocking growth factor receptor signaling using cancer drugs may overcome two challenges: managing oral cancer pain and preventing opioid tolerance. This approach could control cancer while addressing pain through a non-opioid, biologically rational approach.
A Mount Sinai study found that antibody-producing immune cells called IgG1 plasma cells help patients respond to PD-1 immune checkpoint inhibitors, which have transformed cancer care. The researchers identified IgG1 plasma cells as a critical factor in determining clinical outcomes.